ORTX - Orchard Therapeutics plc Stock Price, Fair Value and News

16.70USD Market Closed

Market Summary

USD16.70

Market Closed

ORTX Stock Price

View Fullscreen

ORTX RSI Chart

ORTX Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

-52.13

Price/Sales (Trailing)

174.05

EV/EBITDA

-56.73

Price/Free Cashflow

-40.26

ORTX Price/Sales (Trailing)

ORTX Profitability

EBT Margin

-334.54%

Return on Equity

-90.86%

Return on Assets

-36.05%

Free Cashflow Yield

-2.48%

ORTX Fundamentals

ORTX Revenue

Revenue (TTM)

21.8M

Rev. Growth (Yr)

9.09%

Rev. Growth (Qtr)

-13.84%

ORTX Earnings

Earnings (TTM)

-72.9M

Earnings Growth (Yr)

25.75%

Earnings Growth (Qtr)

-186.98%

Breaking Down ORTX Revenue

Last 30 days

1.5%

Last 90 days

5.0%

Trailing 12 Months

200.0%

How does ORTX drawdown profile look like?

ORTX Financial Health

Current Ratio

3.12

Debt/Equity

0.31

Debt/Cashflow

-3.76

ORTX Investor Care

Shares Dilution (1Y)

1696.60%

Diluted EPS (TTM)

-0.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.4M	21.3M	21.8M	0
2022	7.2M	11.6M	16.2M	22.7M
2021	0	0	3.8M	3.7M
2020	0	3.8M	5.1M	3.2M
2019	0	0	3.3M	4.6M
2018	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Orchard Therapeutics plc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 24, 2024	gaspar bobby	back to issuer	-	-	-366,158	chief executive officer
Jan 24, 2024	dunoyer marc	back to issuer	-	-	-37,179	-
Jan 24, 2024	beck joanne t.	back to issuer	-	-	-9,294	-
Jan 24, 2024	rowland charles a jr	back to issuer	-	-	-12,294	-
Jan 24, 2024	thomas frank e	back to issuer	-	-	-92,081	see remarks
Jan 24, 2024	geraghty james a	back to issuer	-	-	-44,391	-
Mar 10, 2023	thomas frank e	acquired	9,182	0.4591	20,000	see remarks
Feb 09, 2023	thomas frank e	acquired	9,182	0.4591	20,000	see remarks
Apr 01, 2022	gaspar bobby	bought	11,085	0.739	15,000	chief executive officer
Apr 01, 2022	thomas frank e	bought	7,474	0.7474	10,000	see remarks

Which funds bought or sold ORTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 10, 2024	Banque Cantonale Vaudoise	sold off	-100	-7,000	-	-%
Apr 05, 2024	CWM, LLC	sold off	-100	-1,000	-	-%
Apr 05, 2024	Compass Wealth Management LLC	sold off	-100	-149	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	4,524,410	4,524,410	-%
Feb 27, 2024	Beaird Harris Wealth Management, LLC	unchanged	-	105	198	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	695,687	695,687	-%
Feb 15, 2024	GTS SECURITIES LLC	new	-	246,750	246,750	-%
Feb 15, 2024	Blue Owl Capital Holdings LP	new	-	2,631,440	2,631,440	0.63%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-1,000	-	-%
Feb 14, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	sold off	-100	-2,443,990	-	-%

Are Funds Buying or Selling ORTX?

Are funds buying ORTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ORTX

No. of Funds

Unveiling Orchard Therapeutics plc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	6.85%	15,596,600	SC 13G
Feb 14, 2024	ra capital management, l.p.	0.0%	0	SC 13G/A
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	beryl capital management llc	6.9%	15,614,990	SC 13G/A
Oct 16, 2023	beryl capital management llc	5.9%	13,500,000	SC 13G
Apr 10, 2023	federated hermes, inc.	4.57%	840,169	SC 13G/A
Mar 20, 2023	ra capital management, l.p.	9.99%	18,564,300	SC 13G
Mar 20, 2023	deep track capital, lp	9.99%	19,125,150	SC 13G
Feb 13, 2023	chi advisors llc	6.3%	7,987,396	SC 13G/A

Recent SEC filings of Orchard Therapeutics plc

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 08, 2024	SC 13G/A	Major Ownership Report
Feb 05, 2024	15-12G	15-12G
Jan 30, 2024	EFFECT	EFFECT
Jan 30, 2024	EFFECT	EFFECT
Jan 24, 2024	4	Insider Trading
Jan 24, 2024	25-NSE	25-NSE

Peers (Alternatives to Orchard Therapeutics plc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Orchard Therapeutics plc News

Latest updates

Orchard Therapeutics plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2018Q4	2018Q3
Revenue	-13.8%	6,302,000	7,314,000	1,237,000	6,986,000	5,777,000	4,368,000	5,524,000	483,000	1,192,000	-	1,998,000	597,000	595,000	1,918,000	689,000	1,387,000
Costs and Expenses	-6.6%	27,907,000	29,876,000	27,495,000	38,578,000	31,244,000	36,817,000	43,104,000	36,898,000	34,111,000	38,873,000	28,301,000	47,418,000	49,621,000	43,330,000	29,520,000	35,477,000
S&GA Expenses	5.6%	11,609,000	10,992,000	11,135,000	10,600,000	11,496,000	13,730,000	13,299,000	13,552,000	13,039,000	16,226,000	12,956,000	15,659,000	18,531,000	14,223,000	11,952,000	7,466,000
R&D Expenses	-12.8%	14,553,000	16,695,000	15,993,000	25,545,000	18,103,000	21,965,000	28,234,000	23,346,000	20,846,000	22,648,000	14,678,000	31,568,000	30,899,000	28,493,000	17,426,000	27,731,000
EBITDA Margin	19.8%	-3.05	-3.80	-6.54	-6.50	-10.82	-14.16	-22.46	-82.95	-71.71	-57.17	-	-	-	-	-	-
Interest Expenses	-4.4%	932,000	975,000	957,000	933,000	799,000	672,000	675,000	683,000	683,000	575,000	572,000	568,000	-	660,000	-	-
Income Taxes	3804.0%	976,000	25,000	-12,000	-1,121,000	-1,100,000	-219,000	58,000	76,000	-1,100,000	39,000	-500,000	60,000	146,500	-2,200,000	402,000	733,000
Earnings Before Taxes	-179.6%	-34,343,000	-12,282,000	-17,424,000	-9,012,000	-48,649,000	-51,135,000	-44,238,000	-36,224,000	-37,578,000	-33,535,000	-20,831,000	-47,440,000	-45,283,000	-38,931,000	-24,661,000	-33,155,000
EBT Margin	18.4%	-3.35	-4.10	-6.87	-6.75	-11.16	-14.63	-23.24	-85.82	-74.05	-58.85	-	-	-	-	-	-
Net Income	-187.0%	-35,319,000	-12,307,000	-17,412,000	-7,883,000	-47,565,000	-50,916,000	-44,296,000	-36,348,000	-36,445,000	-33,620,000	-20,290,000	-47,500,000	-45,416,000	-36,737,000	-25,063,000	-33,888,000
Net Income Margin	16.4%	-3.34	-4.00	-6.74	-6.65	-11.09	-14.52	-23.21	-86.32	-74.47	-58.57	-	-	-	-	-	-
Free Cashflow	13.6%	-24,018,000	-27,802,000	-30,022,000	-12,568,000	-22,386,000	-27,550,000	-19,997,000	-33,789,000	-17,427,000	-11,951,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2017Q4
Assets	-12.9%	202	232	217	219	234	259	292	322	356	365	389	281	298	315	355	399	415	458	329	366	97.00
Current Assets	-15.1%	154	181	166	168	179	205	237	275	291	304	328	224	234	255	298	350	393	437	319	356	94.00
Cash Equivalents	-38.7%	23.00	38.00	61.00	68.00	81.00	53.00	53.00	56.00	74.00	100	79.00	55.00	41.00	41.00	27.00	19.00	35.00	133	295	336	90.00
Inventory	-4.3%	7.00	7.00	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-8.7%	7.00	8.00	8.00	8.00	8.00	6.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	9.00	8.00	6.00	6.00	6.00	5.00	3.00
Liabilities	-1.0%	122	123	115	121	110	113	116	112	114	100	94.00	103	91.00	88.00	90.00	100	75.00	87.00	42.00	55.00	11.00
Current Liabilities	-14.2%	49.00	58.00	53.00	61.00	50.00	48.00	47.00	43.00	44.00	41.00	48.00	52.00	41.00	42.00	45.00	56.00	44.00	55.00	35.00	48.00	11.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00	25.00	25.00	25.00	-	-	-
Shareholder's Equity	-26.4%	80.00	109	102	98.00	124	146	176	210	241	264	296	178	207	227	265	299	340	371	287	311	86.00
Retained Earnings	-3.8%	-965	-930	-918	-900	-893	-845	-794	-750	-713	-677	-640	-605	-572	-551	-504	-453	-408	-371	-320	-290	-59.74
Additional Paid-In Capital	0.2%	994	992	976	957	953	949	945	941	935	926	920	771	763	757	749	738	731	726	591	587	7.00
Shares Outstanding	0.0%	227	227	184	127	13.00	128	128	126	12.00	12.00	11.00	10.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	74.00	-	-	-	544	-	508,000	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	14.2%	-23,892	-27,833	-29,508	-12,084	-17,928	-26,376	-19,599	-33,396	-16,407	-36,052	-39,242	-11,834	-26,428	-38,110	-49,902	-40,922	-52,092	-29,355	-43,762	-25,550	-30,911
Share Based Compensation	-4.3%	2,468	2,578	3,512	3,926	3,468	3,956	4,660	5,338	5,389	5,541	6,268	6,741	5,663	6,079	9,479	5,671	5,302	4,630	3,821	2,807	1,709
Cashflow From Investing	143.4%	11,581	-26,693	-9,346	-1,564	47,373	19,644	25,107	14,763	-12,737	49,335	-83,526	22,719	26,622	51,224	56,814	22,001	-44,371	-286,459	-529	-312	-887
Cashflow From Financing	-107.6%	-2,352	30,935	31,506	-811	-19.00	-	-	150	4,060	7,422	146,434	1,105	249	1,144	1,438	1,587	-262	156,123	5.00	205,470	147,119

ORTX Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total revenue	$ 6,302	$ 5,777	$ 14,853	$ 15,669
Costs and operating expenses:
Cost of product revenue	1,745	1,645	4,301	4,338
Research and development	14,553	18,103	47,241	68,302
Selling, general and administrative	11,609	11,496	33,736	38,525
Total costs and operating expenses	27,907	31,244	85,278	111,165
Loss from operations	(21,605)	(25,467)	(70,425)	(95,496)
Other income (expense):
Interest income	1,505	404	3,925	686
Interest expense	(932)	(799)	(2,864)	(2,146)
Changes in fair value of PIPE Warrant and PIPE Unit liabilities	(8,801)		3,256
Other income (expense), net	(4,510)	(22,787)	2,059	(47,066)
Total other income (expense), net	(12,738)	(23,182)	6,376	(48,526)
Net loss before income taxes	(34,343)	(48,649)	(64,049)	(144,022)
Income tax benefit (expense)	(976)	1,084	(989)	1,245
Net loss	$ (35,319)	$ (47,565)	$ (65,038)	$ (142,777)
Net loss per ordinary share , basic	$ (0.15)	$ (0.37)	$ (0.35)	$ (1.12)
Net loss per ordinary share , diluted	$ (0.15)	$ (0.37)	$ (0.35)	$ (1.12)
Weighted average ordinary shares outstanding, basic	228,388,561	128,132,092	186,811,772	127,895,426
Weighted average ordinary shares outstanding, diluted	228,388,561	128,132,092	186,811,772	127,895,426
Other comprehensive income:
Foreign currency translation adjustment	$ 3,978	$ 21,459	$ (3,523)	$ 44,504
Unrealized gain (loss) on marketable securities	79	84	114	(177)
Total other comprehensive income (loss)	4,057	21,543	(3,409)	44,327
Total comprehensive loss	(31,262)	(26,022)	(68,447)	(98,450)
Product Revenue, Net [Member]
Total revenue	5,559	5,377	12,744	14,217
Collaboration Revenue [Member]
Total revenue	$ 743	$ 400	$ 2,109	$ 1,452

ORTX Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 23,469	$ 68,424
Marketable securities	101,944	75,326
Accounts receivable, net	6,187	8,467
Inventory	6,638	3,400
Prepaid expenses and other current assets	7,451	6,586
Research and development tax credit receivable	8,234	5,942
Total current assets	153,923	168,145
Non-current assets:
Operating lease right-of-use-assets	20,001	22,774
Property and equipment, net	7,131	8,138
Research and development tax credit receivable	3,372
Restricted cash	4,215	4,215
Intangible assets, net	3,321	3,560
Other assets	10,303	12,075
Total non-current assets	48,343	50,762
Total assets	202,266	218,907
Current liabilities:
Accounts payable	3,661	9,318
Accrued expenses and other current liabilities	29,995	34,437
Deferred revenue	742	959
Operating lease liabilities	5,548	6,424
Notes payable	9,429	9,429
Total current liabilities	49,375	60,567
Notes payable, long-term	16,162	22,991
Deferred revenue, net of current portion	10,345	10,315
Operating lease liabilities, net of current portion	16,681	19,246
PIPE Warrant liabilities	21,068
Other long-term liabilities	8,377	7,524
Total liabilities	122,008	120,643
Commitments and contingencies (see Note 17)
Shareholders’ equity:
Ordinary shares (voting and non-voting), GBP 0.10 par value; Most recent authority to allot up to a maximum nominal value of GBP 33,556,809 and GBP 13,023,851.50 of shares at September 30, 2023 and December 31, 2022, respectively; Issued and outstanding - 227,273,209 and 126,947,225 ordinary shares at September 30, 2023 and December 31, 2022, respectively.	29,463	16,419
Additional paid-in capital	994,108	956,711
Accumulated other comprehensive income	22,609	26,018
Accumulated deficit	(965,922)	(900,884)
Total shareholders’ equity	80,258	98,264
Total liabilities and shareholders’ equity	$ 202,266	$ 218,907

About Orchard Therapeutics plc

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

CEO	Dr. Bobby Gaspar M.D., Ph.D.
WEBSITE	orchard-tx.com
INDUSTRY	Biotechnology
EMPLOYEES	166

Orchard Therapeutics plc Frequently Asked Questions

What is the ticker symbol for Orchard Therapeutics plc? What does ORTX stand for in stocks?

ORTX is the stock ticker symbol of Orchard Therapeutics plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Orchard Therapeutics plc (ORTX)?

As of Fri Feb 02 2024, market cap of Orchard Therapeutics plc is 3.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ORTX stock?

You can check ORTX's fair value in chart for subscribers.

What is the fair value of ORTX stock?

You can check ORTX's fair value in chart for subscribers. The fair value of Orchard Therapeutics plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Orchard Therapeutics plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ORTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Orchard Therapeutics plc a good stock to buy?

The fair value guage provides a quick view whether ORTX is over valued or under valued. Whether Orchard Therapeutics plc is cheap or expensive depends on the assumptions which impact Orchard Therapeutics plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ORTX.

What is Orchard Therapeutics plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 02 2024, ORTX's PE ratio (Price to Earnings) is -52.13 and Price to Sales (PS) ratio is 174.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ORTX PE ratio will change depending on the future growth rate expectations of investors.